SAB Biotherapeutics, Inc. (SABSW) Stock Price & Analysis

SAB Biotherapeutics, Inc. (SABSW) Healthcare & Pipeline Overview

SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of targeted polyclonal antibody therapeutics using its DiversitAb™ platform. The company focuses on addressing unmet needs in infectious diseases, autoimmune diseases, and oncology, operating within the competitive biotechnology sector.

What Is the Investment Thesis for SABSW?

The company's DiversitAb™ platform offers a novel approach to antibody therapeutics, potentially providing advantages over traditional monoclonal antibodies in certain disease areas. Key value drivers include the successful clinical development and commercialization of SAB-142, SAB-176, and SAB-301. The company's P/E ratio of 0.83 suggests undervaluation, but this must be weighed against the inherent risks of drug development. Upcoming clinical trial results for its lead candidates represent significant catalysts. However, potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies.

Based on FMP financials and quantitative analysis

SABSW Key Highlights

SAB Biotherapeutics operates in the biotechnology industry, which is characterized by high growth potential and significant investment in research and development.

• The company's DiversitAb™ platform offers a unique approach to polyclonal antibody therapeutics, potentially providing advantages over traditional monoclonal antibodies.
• SAB Biotherapeutics' pipeline includes product candidates targeting infectious diseases, autoimmune diseases, and oncology, diversifying its risk profile.
• The company's headquarters in Sioux Falls, South Dakota, and additional office in Cambridge, Massachusetts, provide access to talent and resources.
• SAB Biotherapeutics has a beta of 0.61, indicating lower volatility compared to the overall market.

Who Are SABSW's Competitors?

SABSW is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SABSW's Key Strengths?

Proprietary DiversitAb™ platform.

• Diverse pipeline of product candidates.
• Experienced management team.
• Strategic partnerships with leading research institutions.

What Are SABSW's Weaknesses?

Limited financial resources.

• Dependence on successful clinical trial outcomes.
• Competition from established pharmaceutical companies.
• Regulatory hurdles and approval timelines.

What Are the Key Risks for SABSW?

Financial-distress signal — its Altman Z-Score of -0.34 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-6.7%) — the business is not currently generating profit on shareholder capital.
• Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
• Clinical trial failures for lead product candidates.
• Regulatory delays or rejection of marketing applications.
• Competition from established pharmaceutical companies and biosimilars.
• Dependence on securing additional funding to support research and development.
• Intellectual property challenges and patent disputes.

What Are SABSW's Competitive Advantages?

• Proprietary DiversitAb™ platform for polyclonal antibody production.
• Patent protection for its lead product candidates.
• Expertise in developing immunotherapies.
• Established relationships with key opinion leaders in the medical community.

What Does SABSW Do?

SAB Biotherapeutics, Inc., established in 2014, is a biopharmaceutical company dedicated to developing novel immunotherapies. The company's core technology, the DiversitAb™ platform, leverages transgenic cattle to produce human polyclonal antibodies. These antibodies are designed to target a wide range of diseases, including infectious diseases like influenza and MERS-CoV, autoimmune diseases such as Type 1 diabetes, and various oncology indications. SAB Biotherapeutics operates from its headquarters in Sioux Falls, South Dakota, with an additional office in Cambridge, Massachusetts, facilitating collaboration and access to talent in key biotech hubs. SAB's lead product candidates include SAB-142, an anti-thymocyte globulin for Type 1 diabetes, SAB-176 for seasonal influenza, and SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV). The company aims to address critical unmet medical needs by harnessing the power of polyclonal antibody therapeutics.

What Products and Services Does SABSW Offer?

• Develops immunotherapies for infectious diseases.
• Creates treatments for autoimmune diseases.
• Researches and develops therapies for oncology.
• Utilizes the DiversitAb™ platform to produce human polyclonal antibodies.
• Offers SAB-142 anti-thymocyte globulin for Type 1 diabetes.
• Develops SAB-176 for seasonal influenza.
• Creates SAB-301 for Middle East Respiratory Syndrome Coronavirus (MERS-COV).

How Does SABSW Make Money?

• Develops and patents novel immunotherapies.
• Out-licenses or partners with larger pharmaceutical companies for commercialization.
• Generates revenue through milestone payments and royalties.
• Secures government grants and funding for research and development.

What Industry Does SABSW Operate In?

SAB Biotherapeutics operates within the biotechnology industry, a sector characterized by rapid innovation and high growth potential. The competitive landscape includes established pharmaceutical companies and smaller biotech firms focused on developing novel therapeutics. SAB Biotherapeutics differentiates itself through its DiversitAb™ platform, which offers a unique approach to polyclonal antibody production. Key industry trends include the increasing prevalence of chronic diseases, the growing demand for personalized medicine, and the rising adoption of biologics.

Who Are SABSW's Key Customers?

• Patients suffering from infectious diseases.
• Individuals with autoimmune disorders.
• Oncology patients.
• Pharmaceutical companies seeking novel therapeutics.
• Government agencies focused on biodefense.

Company Profile

SAB Biotherapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Miami Beach, US. The company is led by CEO Samuel J. Reich. SABSW has traded publicly since 2021.

Return on equity for SAB Biotherapeutics, Inc. stands at -6.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -22.8%, a gauge of the cash the business throws off relative to its market value. A current ratio of 9.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -4.6%, the inverse of the P/E and a quick read on earnings relative to price.

SAB Biotherapeutics, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -0.34 places it in the distress zone, a signal of elevated financial risk.

SAB Biotherapeutics, Inc. has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 4.0% below estimates on average.

Wall Street analysts project SAB Biotherapeutics, Inc. revenue of about $333K for fiscal 2026, with EPS near $-1.21. The estimate reflects 5 contributing analysts.

Insider Activity

12 transactions · 0 purchases, 0 sales, 12 other transactions · 10 identified insiders · most recent available transactions. Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

SABSW Financials

SABSW Latest News

SABSW Analyst Consensus

SABSW MoonshotScore

Common Questions About SABSW (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources